Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.

@article{Koizumi2012ProspectiveSO,
  title={Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.},
  author={Tomonobu Koizumi and Toshihiko Agatsuma and Kayoko Ikegami and Toshiro Suzuki and Takashi Kobayashi and Shintaro Kanda and Sumiko Yoshikawa and Keishi Kubo and Takayuki Shiina and Keiichirou Takasuna and Akemi Matsuo and Muneharu Hayasaka and Miwa Morikawa and Shingo Ameshima},
  journal={Clinical lung cancer},
  year={2012},
  volume={13 6},
  pages={458-63}
}
INTRODUCTION Salvage treatment for acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor in patients with non-small-cell lung cancer is a matter of clinical concern. Several retrospective reports have indicated the usefulness of epidermal growth factor receptor tyrosine kinase inhibitor readministration; however, there have been few prospective studies. MATERIALS AND METHODS This study was designed to prospectively evaluate the clinical efficacy of gefitinib… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer

Cancer Chemotherapy and Pharmacology • 2015
View 2 Excerpts

Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer

EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] • 2013
View 2 Excerpts

Similar Papers

Loading similar papers…